Bradley Bernstein, MD, PhD Dana-Farber Cancer Institute
Bernstein and colleagues will work to identify altered epigenetic states and drivers in small intestine and pancreatic neuroendocrine tumors to identify new treatment strategies for patients. In parallel the team will also work to develop neuroendocrine tumor models. These models will be used to assess potential new biomarkers and will also facilitate future research projects.
- Deep characterization of genome-wide chromatin states in primary human small intestine tumor and pancreatic neuroendocrine tumor samples, with the goal to determine the gene regulatory circuits and aberrant epigenetic states that sustain these tumors and may thus represent therapeutic opportunities.
- Generation of stable neuroendocrine tumor models to assess new biomarkers in carcinoid tumors and their associated stroma and to determine the significance of particular histone modifications through future perturbation studies.
- City: Boston
- State: Massachusetts
- Grant Duration: 2 years
- Awards: No information
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.